C O V E R S T O R Y
genotypic data from the diagnostics business and in-house analytics capabilities through the bioinformatics platform ,” adds Dr Ramprasad .
The space and business have evolved rapidly over the last few years . MedGenome ’ s diagnostic testing is expanding to emerging economies . It has acquired companies within India to expand our geographic footprint and reach across the country . Globally our research is focussing on omics solutions for pharma and academic partners enabling wider drug discovery initiatives .
The company has two business lines - with our diagnostics business growing at a more than 25 % growth rate . It expects to continue to growing at this rate for the coming years . The research solutions cater to academic and pharma clients in the USA . The potential is huge and with the wide range of omics services , it is set to explore the potential significantly in the next few years . Since this is a dynamic field , and company ’ s leadership expects innovations to drive this business in the long term .
Market Potential
The broader genomics market has expanded , primarily due to increased awareness stemming from the COVID pandemic . However , the company sees this growth in larger cities and tertiary
care settings . To make a more substantial impact , broadening its reach to primary and secondary areas will bring about transformative effects on a much larger scale .
Surajit Chakrabartty , CFO , MedGenome informs : “ We have two business lines - with our diagnostics business growing at a more than 25 % growth rate . We expect to continue to grow at this rate for the coming years . Our research solutions cater to academic and pharma clients in the US . The potential is huge and with the
20
BioVoiceNews | January / February 2024